In breast cancer, HER-2 blockade may improve the response to endocrine therapy, because the interaction between HER-2 and hormone receptor pathways can lead to endocrine therapy resistance (Johnston et al., 2021). This evidence concerns the gene ERBB2 and breast carcinoma.